Kythera Biopharmaceuticals Inc. (NASDAQ: KYTH) was reinstated as Buy with a $66 price objective (versus a $47.00 close) at Merrill Lynch. The firm’s analysis is based on longer discounted cash flow estimates as the company is taking a shot at double chins.
Read more: Top Analyst Upgrades and Downgrades: Apple, Citrix, Kythera, Mylan, Netflix, Weatherford and More - Apple Inc. (NASDAQ:AAPL) - 24/7 Wall St. http://247wallst.com/investing/2015/04/10/top-analyst-upgrades-and-downgrades-apple-citrix-kythera-mylan-netflix-weatherford-and-more/#ixzz3Ww4rsnyk
Follow us: @247wallst on Twitter | 247wallst on Facebook
exceeding in us alone, excluding off label use. so intl, etc. very possible